Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammator…

Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific ...
Fierce Biotech

Caldera launches with $112M, former Morphic CEO and IBD drug from China

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since being founded last year, Caldera has already taken the therapy, dubbed CLD-423, ...
BioPharma Dive

Caldera starts up with $112.5M and a dual-targeting immune drug from China

The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.
SiliconANGLE

Caldera raises $15M to help developers deploy their own scaling for blockchain networks

Caldera, a Web3 infrastructure platform that helps developers deploy Ethereum rollups for scaling up blockchain networks, today announced it has raised $15 million in an early-stage funding round.

Caldera introduces revolutionary heated and therapy solutions for pets

Discover how Caldera International is transforming pet care with innovative heated and therapeutic solutions for improved comfort and health. CANBY, OR, UNITED STATES, January 6, 2026 ...